Post-treatment Visual Acuity Prediction Using Deep Learning in Age-related Macular Degeneration

被引:0
|
作者
Kim, Najung [1 ]
Kim, Hyung Chan [1 ]
Chung, Hyewon [1 ]
Lee, Hyungwoo [1 ,2 ]
机构
[1] Konkuk Univ, Med Ctr, Sch Med, Dept Ophthalmol, Seoul, South Korea
[2] Konkuk Univ, Med Ctr, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 05030, South Korea
来源
JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | 2023年 / 64卷 / 07期
基金
新加坡国家研究基金会;
关键词
Age-related macular degeneration; Deep learning; Prediction; Visual acuity; RISK-FACTORS; RANIBIZUMAB; PREVALENCE; OUTCOMES; THERAPY;
D O I
10.3341/jkos.2023.64.7.582
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To develop a deep learning model to predict visual acuity (VA) outcomes after 12 months of anti-vascular endothelial growth factor (anti-VEGF) treatment.Methods: A total of 330 treatment-naive eyes of neovascular age-related macular degeneration patients, who underwent anti-VEGF therapy between 2007 and 2020 at Konkuk University medical center, were included. The network was trained using VA at baseline, VA after three loading doses of anti-VEGF, and treatment regimen data. It was also trained using 12,300 augmented optical coherence tomography (OCT) B-scan images at baseline and after three loading doses of anti-VEGF. We generated five deep learning models using sequentially input data (VA and OCT B-scan images at baseline and after three loading doses, and treatment regimen). Prediction of VA at 12 months was performed using deep learning algorithms, such as convolutional neural network and multilayer perceptron. The outcomes were dichotomized based on whether the decremental change in VA during the 12 months of treatment was more or less than logarithm of the minimum angle of resolution 0.3. Predictive efficiency was assessed by comparing the performance of deep learning models.Results: The best performing model was trained using input data, including VA at baseline and after three loading doses, treatment regimen, and OCT B-scan images at baseline and after three loading doses. The decremental outcome in VA after 12 months of anti-VEGF treatment was predicted as an area under the curve (AUC) of 0.79. The addition of OCT images at baseline and after three loading doses as input data improved the AUC, sensitivity, and negative predictive value (AUC 0.74-0.79, 0.58-0.86, and 0.90-0.95, respectively). Conclusions: Our deep learning model showed relatively good performance in classifying good or poor post-treatment VA based on combined clinical information including numerical and image data. J Korean Ophthalmol Soc 2023;64(7):582-590
引用
收藏
页码:582 / 590
页数:9
相关论文
共 50 条
  • [31] Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration
    Ian J Constable
    Ian L McAllister
    Timothy Isaacs
    International Journal of Ophthalmology, 2011, (01) : 85 - 88
  • [32] Intravitreal bevacizumab for age-related macular degeneration with good visual acuity
    Maki Takahashi
    Taku Sato
    Shoji Kishi
    Japanese Journal of Ophthalmology, 2010, 54 : 565 - 570
  • [33] Neovascular Age-Related Macular Degeneration Disease Quiescence with Visual Acuity Stability in a Subgroup of Patients Following PRN Treatment
    Fliney, Greg D.
    Zukin, Leonid M.
    Hagedorn, Curtis
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2017, 33 (08) : 604 - 609
  • [34] Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life
    Cazet-Supervielle, Agathe
    Gozlan, Julien
    Cabasson, Severin
    Boissonnot, Michele
    Manic, Helene
    Leveziel, Nicolas
    OPHTHALMOLOGICA, 2015, 234 (01) : 26 - 32
  • [35] Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
    Ross, A. H.
    Donachie, P. H. J.
    Sallam, A.
    Stratton, I. M.
    Mohamed, Q.
    Scanlon, P. H.
    Kirkpatrick, J. N.
    Johnston, R. L.
    EYE, 2013, 27 (01) : 56 - 64
  • [36] Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
    Jaffe, Glenn J.
    Martin, Daniel F.
    Toth, Cynthia A.
    Daniel, Ebenezer
    Maguire, Maureen G.
    Ying, Gui-Shuang
    Grunwald, Juan E.
    Huang, Jiayan
    OPHTHALMOLOGY, 2013, 120 (09) : 1860 - 1870
  • [37] Relationship between foveal birefringence and visual acuity in neovascular age-related macular degeneration
    A Weber
    A E Elsner
    M Miura
    S Kompa
    M C Cheney
    Eye, 2007, 21 : 353 - 361
  • [38] INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH GOOD BASELINE VISUAL ACUITY
    Saito, Masaaki
    Iida, Tomohiro
    Kano, Mariko
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (07): : 1250 - 1259
  • [39] Prediction of postoperative visual acuity in patients with age-related cataracts using macular optical coherence tomography-based deep learning method
    Wang, Jingwen
    Wang, Jinhong
    Chen, Dan
    Wu, Xingdi
    Xu, Zhe
    Yu, Xuewen
    Sheng, Siting
    Lin, Xueqi
    Chen, Xiang
    Wu, Jian
    Ying, Haochao
    Xu, Wen
    FRONTIERS IN MEDICINE, 2023, 10
  • [40] Visual acuity and progression of macular atrophy in patients receiving intravitreal anti-VEGF for age-related macular degeneration
    Ji, Marco H.
    Callaway, Natalia F.
    Ludwig, Cassie A.
    Vail, Daniel
    Al-Moujahed, Ahmad
    Rosenblatt, Tatiana R.
    Leng, Theodore
    Sanislo, Steven R.
    Moshfeghi, Darius M.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : 429 - 435